Business
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy dataAlpibectir: Phase 2a EBA trial delivered very strong proof of conceptPreclinical candidates from BioVersys’ two proprietary platforms continue to progressFull Year 2024 operating income of CHF 1.2 million and net loss of CHF 18.7 millionSuccessful financing activities in 2024, including Series C financing round of app
About this update from Bioversys Ag
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR","length":97,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Alpibectir: Phase 2a EBA trial delivered very strong proof of concept","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical candidates from BioVersys’ two proprietary platforms continue to progress","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Full Year 2024 operating income of CHF 1.2 million and net loss of CHF 18.7 million","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful financing activities in 2024, including Series C financing round of approximately CHF 15 million and USD 6 million investment from GIBF (Guangzhou Israeli Biotech Fund) ","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"CHF 32.6 million in cash and cash equivalents plus current financial assets on December 31, 2024","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful IPO on SIX Swiss Exchange on February 7, 2025, further reinforcing BioVersys’ financial position with CHF 76.7 million raised, allowing to finance operations into 2028 ","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Outlook: BV100 Phase 3 program to be initiated in H2 2025; additional Alpibectir Phase 2 studies in pulmonary Tuberculosis started in H1 2025 and are to be started H1 2026 in meningeal Tuberculosis","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call on March 26, 2025 at 2.00 pm CET (8.00 am EST)","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1037,"olType":false},{"type":"text","con...